T细胞上TIM-3检查点受体表达与慢性髓性白血病无治疗缓解的关联
该研究在44例停用酪氨酸激酶抑制剂(TKI)的慢性髓性白血病(CML)患者中,检测T细胞亚群、调节性T细胞(T-regs)和自然杀伤(NK)细胞上免疫检查点分子的表达,其中22例维持无治疗缓解(TFR)、22例发生分子学复发(MolR)。MolR组T-regs绝对数较TFR组增加,TIM-3在CD3+、CD4+、CD8+ T细胞及T-regs上持续上调,而PD-1、CTLA-4、LAG-3、TIGIT无差异表达。
要点
- 停用TKI时,MolR组T-regs绝对数较TFR组增加。
- TIM-3在MolR组CD3+、CD4+、CD8+ T细胞及T-regs上较TFR组持续上调。
- PD-1、CTLA-4、LAG-3、TIGIT在T或NK细胞上MolR组与TFR组无差异表达。
核心结论
- 在可靶向的免疫检查点分子中,TIM-3阻断可能改善停用TKI的CML患者的效应免疫应答,同时靶向白血病干细胞,可能是预防停用TKI后复发的有前景的治疗策略。
研究设计与样本
- 在44例停用TKI的CML患者中评估T细胞亚群、T-regs和NK细胞上PD-1、TIM-3、CTLA-4、LAG-3和TIGIT的表达,其中22例维持TFR、22例发生MolR。
- 利用公开数据集进行基因表达分析,比较CML干细胞与正常造血干细胞中TIM-3的表达。
主要发现
- MolR组T-regs绝对数较TFR组增加,证实了既往发现。
- PD-1、CTLA-4、LAG-3和TIGIT在T或NK细胞上MolR组与TFR组无差异表达。
- TIM-3在MolR组CD3+ T细胞、CD4+ T细胞、CD8+ T细胞和T-regs上较TFR组持续上调。
- 公开数据集基因表达分析显示,CML干细胞中TIM-3表达较正常造血干细胞增加。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dysregulation of immune-checkpoint receptors has been reported at diagnosis of chronic myeloid leukemia (CML), however, their role in the maintenance of remission after tyrosine kinase inhibitor (TKI) cessation is unclear. We assessed programmed cell death-1 (PD-1), T-cell immunoglobulin, and mucin-domain containing protein-3 (TIM-3), cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), lymphocyte-activation gene-3 (LAG-3), and T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) expression on T-cell subsets, regulatory T cells (T-regs), and natural killer (NK) cells at the time of TKI cessation in 44 patients (22 patients sustained treatment-free remission [TFR] and 22 experienced molecular relapse [MolR]). We confirmed our previous finding that absolute numbers of T-regs are increased in patients who experienced MolR compared with those who sustained TFR. The immune-checkpoint receptors PD-1, CTLA-4, LAG-3, and TIGIT on T or NK cells were not differentially expressed between the MolR and TFR groups. However, TIM-3 was consistently upregulated on bulk T cells (CD3+) and T-cell subsets including, CD4+ T cells, CD8+ T cells, and T-regs, in patients who relapsed in comparison with those who maintained TFR after discontinuation. Furthermore, gene expression analysis from publicly available data sets showed increased TIM-3 expression on CML stem cells compared with normal hematopoietic stem cells. These findings suggest that among the targetable immune-checkpoint molecules, TIM-3 blockade may potentially improve effector immune response in patients with CML stopping TKI, while concomitantly targeting leukemic stem cells and could be a promising therapeutic strategy for preventing relapse after cessation of TKI in patients with CML.
引用
- Irani YD, Kok CH, Clarson J, et al. Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia. Blood Adv. 2023. PMID: 36622326. doi:10.1182/bloodadvances.2022008854
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。